![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif)
doxorubicin hydrochloride![Patient Information Patient Information](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/btn-patient-info.gif) The hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif)
Synonyms: | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | ADR chloridrato de doxorrubicina | | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | US brand names: | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | Adriamycin PFS Adriamycin RDF | | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | Foreign brand names: | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | Adriacin Adriblastina Adriblastine Adrimedac DOXO-CELL Doxolem Doxorubin Farmiblastina Rubex | | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | Abbreviations: | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | ADM Adria DOX | | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | Code name: | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | FI-106 | | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | Chemical structure names: | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) | - 14-hydroxydaunorubicin hydrochloride
- 3-hydroxyacetyldaunorubicin hydrochloride
- 5,12-naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-(9CI)
- L-lyxo-hexopyranoside, 3b-glycol-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1a-naphthacenyl 3-amino-2,3,6-trideoxy-.alpha.-, hydrochloride
| | ![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090509150617im_/http://www.cancer.gov/images/spacer.gif) |